A regional assessment of the Spina Bifida Market region reveals a dichotomy driven by public health initiatives and healthcare infrastructure. North America and Europe, which have high rates of mandatory folic acid food fortification, have seen incidence rates decline, yet still dominate market revenue due to high per-capita healthcare expenditure and comprehensive reimbursement for lifelong care—especially for costly shunts, IUCs, and rehabilitation. These regions are also the primary centers for high-cost fetal surgery and advanced rehabilitation technology.

Conversely, the Asia-Pacific (APAC) and emerging markets, despite having a generally higher birth incidence due to lower rates of mandatory fortification and prenatal screening, currently contribute less to market revenue. However, the APAC region is projected to be the fastest-growing market segment. This growth is fueled by increasing government focus on reducing neural tube defects through fortification programs, coupled with rapid modernization of pediatric neurosurgical and urological services, which will bring more diagnosed patients into the formal chronic care pathway. The sheer volume of patients in countries like China and India, once formally diagnosed and provided with consumables, represents the largest potential for long-term volume growth in the market.